A New Class of Immunotherapies

Everyone Deserves a Long and Healthy Life 

At IMV, we believe that everyone deserves effective cancer treatments that respect patients’ quality of life. Our unique DPX technology gives us the ability to create a new class of immunotherapy that generates targeted and long-lasting immune activation with limited side effects. With this unique ability, we are dedicated to improving cancer treatment and giving everyone a chance to enjoy a long and healthy life.  

About IMV 

Our response to COVID-19 outbreak 

Our DPX Platform

Our DPX Platform

A Versatile Technology That Generates a Targeted, Robust and Sustained Immune Response

Thanks to its unique “no release” delivery system, our proprietary DPX delivery platform can be formulated with peptide antigens to induce a specific, robust, and sustained immune response. IMV is leveraging this mechanism of action to generate “first-in-class” T cell therapies for patients facing cancer. In the context of infectious diseases, the DPX platform can also be formulated with B cell epitopes to target virus’ specific regions like spike proteins of the SARS-CoV2.

Our Lead Candidate: DPX-Survivac

Our Lead Candidate: DPX-Survivac

One Immunotherapy to Tackle Both Solid and Hematologic Tumors

Our lead asset, DPX-Survivac, is a T cell activating immunotherapy which combines the advantages of the DPX platform and the cancer antigen survivin. DPX-Survivac generates in vivo a constant flow of T cells that target cancer cells expressing survivin, a promising tumor-associated target overexpressed in a high percentage of tumor types.

About DPX-Survivac
Our Vaccine Candidate against COVID-19

Our Vaccine Candidate against COVID-19

A Targeted Approach to Eliminate the Virus and Limit the Infection

In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-19 pandemic. IMV believes its targeted peptide epitope approach has the potential to optimize and exceed the safety and efficacy profile of more conventional vaccines. This peptide-based approach, combined with the advantages of the DPX platform, offers the potential for accelerated development and rapid, large-scale production of a vaccine against COVID-19.

About DPX-COVID-19

Email Alerts

Stay informed and receive company updates straight to your inbox.

Stock Information

Stock Information